KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short term Debt (2023 - 2025)

Rigel Pharmaceuticals has reported Short term Debt over the past 3 years, most recently at $29.8 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 309.96% year-over-year to $29.8 million; the TTM value through Dec 2025 reached $29.8 million, up 309.96%, while the annual FY2025 figure was $29.8 million, 309.96% up from the prior year.
  • Short term Debt for Q4 2025 was $29.8 million at Rigel Pharmaceuticals, roughly flat from $29.8 million in the prior quarter.
  • Over five years, Short term Debt peaked at $29.8 million in Q4 2025 and troughed at $7.2 million in Q4 2023.
  • A 3-year average of $18.0 million and a median of $14.8 million in 2025 define the central range for Short term Debt.
  • On a YoY basis, Short term Debt climbed as much as 309.96% in 2025 and fell as far as 0.24% in 2025.
  • Year by year, Short term Debt stood at $7.2 million in 2023, then increased by 0.59% to $7.3 million in 2024, then soared by 309.96% to $29.8 million in 2025.
  • Business Quant data shows Short term Debt for RIGL at $29.8 million in Q4 2025, $29.8 million in Q3 2025, and $22.4 million in Q2 2025.